Targeted biologic therapies in the management of moderate-to-severe plaque psoriasis
This 15-minute Clinical Brief newsletter offers a brief overview of targeted biologic therapies for the management of plaque psoriasis, focussing on the role of the interleukin-17 inhibitor, ixekizumab.
Sign up for free and continue reading
Med CPD offers the widest range of courses and content, all accessible in one place. Click on the Sign up button and start looking after the health of your career.